ER、PR、Her2／neu 在甲状腺乳头状癌中的表达及临床意义

摘要

目的：观察 ER、PR 和 Her2／neu 在甲状腺乳头状癌（papillary thyroid carcinoma，PTC）中的表达情况，并分析 ER、PR 和 Her2／neu 的表达与 PTC 的临床病理特征及其预后的关系。方法：采用免疫组化 SP 两步法检测108例 PTC、20例甲状腺滤泡性腺瘤及10例正常甲状腺组织标本中 ER、PR、Her2／neu 的表达，采用荧光原位杂交技术检测 Her2／neu 基因的表达。结果：ER、PR 在 PTC 组高表达，明显高于腺瘤组及正常组，应用免疫组化法和荧光原位杂交检测各组均未见 Her2／neu 表达；ER、PR、Her2／neu 的表达与患者年龄、性别、淋巴结是否转移及患者预后无显著相关性。结论：ER、PR 在 PTC 中表达敏感性较高，可以作为鉴别甲状腺良、恶性肿瘤的有效指标。Her2／neu 在 PTC 中无表达，其与 PTC 患者预后无关，与 Her2／neu 相关的靶向治疗药物不可应用于 PTC 的治疗。%Objective:To evaluate the expression of ER,PR and Her2 eu,and to analyze the correlation between expression and clinical outcomes in papillary thyroid carcinoma.Methods:Immunohistochemistry was used to detect the expression of ER,PR and Her2 eu,fluorescent in situ hybridization was used to detect the amplification state of Her2 eu gene in 108 cases of papillary thyroid carcinoma,20 cases of thyroid adenoma and 10 cases of normal thy-roid tissue.Results:The expression of ER and PR were significally different between control group and PTC,the pro-tein expression and the gene amplification of Her2 eu were not detected by immunohistochemical technique or fluo-rescent in situ hybridization in the histological samples of papillary thyroid carcinoma,whereas ER,PR and Her2 eu had no correlation with the clinical features of papillary thyroid carcinoma.Conclusion:ER and PR are useful biomar-kers for the pathological diagnosis of PTC.Her2 eu is nonspecific and has no contribution to the development of pa-pillary thyroid carcinoma.It can not be used as a molecular target for treatment of thyroid papillary carcinoma.